Drug Trial Radar · NCT02287779
Safety and Tolerability Study of SHP626 in Overweight and Obese Adults
Last checked: Nov 19, 2026Latest source record: Mar 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Jan 19, 2015
Primary completion
Jun 19, 2015
Study completion Jun 19, 2015
Sponsor
- Lead sponsor
- Mirum Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 11, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will investigate the safety and tolerability of daily dosing regimens of SHP626 in overweight and obese adults.
Conditions
- Non-Alcoholic Steatohepatitis
Interventions
SHP626Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Standard HematologyTime frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Fat Soluble Vitamins (Vitamin A, D, & E)Time frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Lipid PanelTime frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Thyroid Hormone PanelTime frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to CoagulationTime frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Standard ChemistryTime frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Urinalysis ParametersTime frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Vital SignsTime frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Electrocardiogram (12-lead)Time frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Treatment-emergent Adverse Events (STEAEs)Time frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) Who Discontinued From the StudyTime frame: From the start of the study drug administration up to 9 days after the last dose of study drug administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
New Orleans Center for Clinical Research
Knoxville, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.